"Real Housewives of Beverly Hills" star Teddi Mellencamp was hospitalized with Stevens-Johnson syndrome after an allergic reaction to medication while battling Stage 4 melanoma.

SkylineDx today announced the launch of the Guideline-Informed Risk Assessment Initiative, a clinical program designed to support surgeons and multidisciplinary teams in evaluating patients with T1 ...

Wrapped in velvety-soft, body-safe silicone, the Peach is shaped to fit naturally in your hand. With 14 intensity levels, you can fine-tune the pace—whether it’s soft and gentle or powerful and ...

The study — which surveyed almost 4,000 south-east Queensland children — found average mole count plummeted from 87 in 1992 to 46 in 2016 — a 47 per cent reduction.

When Dr. Wiese examined her back, he found the culprit behind the sister’s concern: a dilated pore of Winer, which is a benign (non-cancerous) condition—essentially a greatly enlarged pore that ...

burnd is proud to have officially partnered with AIM at Melanoma, Veteran Golfers Association (VGA), Honcho Pickleball, and the National Ski Patrol (NSP). These partnerships reflect burnd's commitment ...

A new study published in JAMA Dermatology suggests U.S. veterans exposed to Agent Orange may face a higher risk of developing acral melanoma — a rare and often late-diagnosed form ...

IDEAYA Biosciences (NASDAQ:IDYA) executives outlined multiple upcoming clinical catalysts at Citi’s 2026 Virtual Oncology ...

Podiatrists have issued a warning to anyone with discoloured toenails, urging them to see a doctor immediately. Podiatrists, medical professionals devoted to the treatment of disorders of the foot, at ...

Researchers at Oregon State University have developed and tested in a mouse model a new type of nanoparticle that enables the removal of melanoma tumors with a low-power laser. After the systemically ...

Dear Dr. Roach: I was recently diagnosed with superficial spreading melanoma. I had a wide excision and was told to follow up with a dermatologist. The dermatologist says to follow up every six months ...

A breakthrough personalized mRNA cancer vaccine that trains the immune system to target patients' unique tumor mutations is showing promising results. Five-year trial data show the risk of recurrence ...